TrialsgrambetaRCTs are beautiful

BLISS-LN

2020

Belimumab in Lupus Nephritis

In 448 patients with active lupus nephritis, adding belimumab to standard therapy increased renal response at week 104 compared with placebo.

Result

Efficacy: Primary efficacy renal response at week 104OR 1.55 (CI 1.04-2.32) · P = 0.03

Below 1 favours placebo, above 1 favours belimumab to standard therapy.

Event rates
Absolute difference
11 points
NNT
10

Absolute difference and NNT are derived from the event rates.

Also reported: Renal-related event or death HR 0.51.

Original publication
Subtopic
Lupus nephritis
Design
Phase 3 double-blind RCT
Relevance
Important: one of several pillars.
Source
Furie R, et al. N Engl J Med. 2020;383(12):1117-1128.doi 10.1056/NEJMoa2001180

Discussion & critique

First biologic approved specifically for lupus nephritis; KDIGO 2024 add-on for active disease.

Discussed in podcasts